The health‑tech startup THE PHAGE has closed a ¥570 million Series A round aimed at building artificial‑intelligence models that track glucose levels and enable personalized, preventative health solutions.
Tokyo‑based health‑tech startup THE PHAGE has secured a ¥570 million Series A round to develop AI‑driven glucose‑monitoring technology aimed at preventive care.
Funding round details
The financing was led by a consortium of Japanese venture capital firms, with participation from strategic corporate investors. The capital will be allocated to building proprietary machine‑learning models that can continuously predict blood‑glucose fluctuations from wearable sensor data.
AI model development
THE PHAGE plans to train deep‑learning algorithms on anonymized datasets collected from early‑stage clinical trials. The models will generate personalized glucose forecasts, alerting users to potential spikes or drops before they occur, thereby supporting lifestyle adjustments and early medical intervention.
Market potential and preventive health
By shifting focus from reactive treatment to proactive monitoring, the startup aims to tap into Japan’s growing preventive‑health market, which is driven by an aging population and rising prevalence of metabolic disorders.
- Continuous glucose monitoring via non‑invasive wearables
- Real‑time AI alerts delivered to smartphones
- Personalized diet and activity recommendations
- Integration with electronic health records for clinician oversight
The Series A round positions THE PHAGE to accelerate product development, expand its research collaborations, and begin pilot deployments with healthcare providers in major Japanese cities.
“Our vision is to empower individuals with actionable insights that keep them healthy, not just treat disease after it manifests,” said CEO Yuki Tanaka.
Comments
No comments yet.